Latest event summaries
Event summaries combining transcripts, slides, and related documents. Updated as new events are published.
- H1 FY27 capacity rose 24% as energy sales climbed 32%.ADANIGREEN
Investor presentation - Q2 revenue and profit rose YoY, but margins narrowed and borrowings increased.DMART
Q2 26/27 - Subscription sales and funded partnerships are advancing; financing is the key to scaling into 2027.VPT
Investor update - All four proposals passed preliminarily, including annual say-on-pay voting.MMED
AGM 2026 - Sale proposal won 99.8% preliminary support; closing targets year-end, pending approvals.GTE
EGM 2026 - Reverse split and up-listing plans advanced alongside broader quantum software initiatives.ZPTA
AGM 2026 - Record FY2026 sales and net income, with strong cash generation despite margin pressure.ODC
Q4 2026 - Four proposals passed preliminarily; reverse-split voting continued through Oct. 30.ISPC
AGM 2026 - WELTRUZA approval adds a second long-acting injectable royalty stream.MEDCL
Investor update - Adjusted revenue rose 16%; FY26 free cash flow target is ~$2.5B despite fuel pressure.DAL
Q3 2026 - High-growth volumes and margin expansion cushioned weaker earnings and 4.7x leverage.CAML3
Q2 2027 (Q&A) - Car trade drove revenue growth, but Q3 net profit fell and net debt rose.TKM1T
Q3 2026 - Cavorite X7 targets Q1 2027 completion, backed by >$70M cash and LOIs.HOVR
Q1 2027 - Strategic reset targets asset-light growth and shareholder returns amid softer sales.MTY
Q3 2026 - Multi-target I&I biologics, early PoC signals and urgent capital needs define the IPO.BBTX
Registration filing - Proposals cover a reverse split, Ontario continuance, preferred shares and five board nominees.IBAT
Proxy filing